Biomolecules & Therapeutics : eISSN 2005-4483 / pISSN 1976-9148

Download original image
Fig. 3. Effect of efonidipine on the production of pro-inflammatory mediators in LPS-stimulated BV2 and HMC3 cells. (A, B) BV2 cells were co-treated with LPS (1 µg/mL) and the indicated concentrations of efonidipine for 24 h. The concentrations of IL-1β (A) and NO (B) in the culture media were determined using a commercial ELISA kit and Griess reaction, respectively, as described in the Materials and methods. (C) HMC3 cells were co-treated with LPS (0.1 µg/mL) and the indicated concentrations of efonidipine for 24 h, and the concentration of IL-1β in the cell lysate was determined using a commercial ELISA kit, as described. The absorbance was measured using a microplate reader. The data are presented as the mean ± SEM of at least three independent experiments (#p<0.05 vs. vehicle-treated control cells; *p<0.05 vs. LPS-treated cells). LPS: lipopolysaccharide.
Biomolecules & Therapeutics 2022;30:455~464 https://doi.org/10.4062/biomolther.2022.076
© Biomolecules & Therapeutics